

**What is claimed is:**

1. An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding human TRADD, wherein said antisense compound inhibits the expression of  
5 human TRADD.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

10 3. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 21, 24, 25, 26, 27, 29, 31, 32, 34, 35, 36, 38, 39, 40, 41, 43, 44, 46, 47, 50, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 71, 72, 73,  
15 75, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises SEQ ID NO: 9, 17, 26, 27, 34, 47, 50, 52, 55, 58, 61, 68, 69, 72, 78, 85 and 86.

5. The antisense compound of claim 2 wherein the  
20 antisense oligonucleotide comprises at least one modified internucleoside linkage.

6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate  
25 linkage.

7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

8. The antisense compound of claim 7 wherein the  
30 modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

10. The antisense compound of claim 9 wherein the  
5 modified nucleobase is a 5-methylcytosine.

11. The antisense compound of claim 2 which is a chimeric oligonucleotide.

12. A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically  
10 acceptable carrier or diluent.

13. The pharmaceutical composition of claim 12 further comprising a colloidal dispersion system.

14. The pharmaceutical composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

15 15. A method of inhibiting the expression of TRADD in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of TRADD is inhibited.

16. A method of treating a human having a disease or  
20 condition associated with TRADD comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of TRADD is inhibited.

17. The method of claim 16 wherein the disease or  
25 condition is septic shock, inflammation, or cancer.